GSK blood cancer drug nearly halves risk of death in late-stage trial

- GSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood cancer, according to data from a late-stage study presented at a medical meeting on Sunday.

Detailed data from the trial was presented at the American Society of Clinical Oncology meeting in Chicago on Sunday. More than half of the Blenrep patients were alive without disease progression after a median follow-up of 21.8 months compared with 12.7 months PFS for the standard of care, the company said.

Treatments for multiple myeloma include Johnson & Johnson's Darzalex and other generic cancer drugs. The U.S. FDA in April approved two cell therapies - J&J's Carvykti, and Bristol Myers' Abecma - as earlier lines of treatment in less severe multiple myeloma.

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

GSK blood cancer drug nearly halves risk of death in late-stage trialExplore stories from Atlantic Canada.
Source: SaltWire Network - 🏆 45. / 63 Read more »